Company intelligence / Profile preview

eGene

Irvine, California, USA

Ownership: Private
Development stage: Other

Overview

eGene was a biotechnology company specializing in the development and commercialization of genetic analysis systems. The company's core technology was a multi-channel capillary electrophoresis system designed for high-resolution DNA and RNA analysis. Its flagship product, the HDA-GT12, provided automated, high-throughput solutions for laboratories performing genetic testing and molecular diagnostics. In 2007, eGene was acquired by Qiagen, which integrated the technology into its QIAxcel product line. This acquisition allowed Qiagen to offer a more comprehensive suite of sample and assay technologies for the life sciences market.

Therapeutic areas: OtherRare Diseases
Modalities: Device
Industry: Molecular Diagnostics

Beyond the preview

Go deeper on eGene.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on eGene.

Explore the full profile